Medline Database
The National Library of Medicine's Medline Database is a free, online research
tool that can be used to access clinical information from over 5,000 medical journals
published worldwide. For more information on Medline and how to use it, click on
the link below.
|
|
|
|
|
|
Important Treatment Considerations
- Evaluate serum ALT levels every month during the first 3 months
of treatment, and every 3 months during the remainder of the first year. Thereafter,
serum ALT levels should be periodically evaluated more frequently in patients who
develop elevations. Rilutek should be discontinued if ALT levels increase to 5 times
ULN or if clinical jaundice develops.
- Advise patients about the potential for dizziness, vertigo, or
somnolence and not to drive or operate machinery until they have sufficient experience
on Rilutek.
- Advise patients to report any febrile illness; measure WBCs.
- Use Rilutek with caution in patients with concomitant liver insufficiency;
caution should be exercised when prescribing Rilutek to patients taking drugs that
are potentially hepatotoxic or highly protein bound:
- Interactions may also occur when riluzole is given concurrently
with agents that affect hepatic CYP 1A2 activity.*
|
|
|
|
|
|
|
|
|
|